Open AccessAnti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia
Author(s) -
Pongdhep Theerawit
Publication year - 2021
Publication title -
clinical critical care
Language(s) - English
Resource type - Journals
ISSN - 2774-0048
DOI - 10.54205/ccc.v29i.252686
Subject(s) - medicine , corticosteroid , pneumonia , complication , covid-19 , immunology , intensive care medicine , disease , infectious disease (medical specialty)
The SARs-CoV-2 results in hyperinflammation among infected patients. This condition leads to serious organ injury, especially in the lungs. Therefore, the main treatment option, in addition to anti-viral agents, is the administration of corticosteroids. However, in many cases, inadequate response to corticosteroids has been observed—other anti-inflammatory agents, such as interleukin-6 inhibitor, kinase inhibitor, etc., play an essential role in reducing this severe complication.